The MAB will help STO maximize its global impact and improve equitable patient access to safe, effective, and affordable innovative new medicines.

STO is pleased to announce the addition of Drs. Sean Khozin, Ke Liu, Mace L. Rothenberg, and Lillian L. Siu to its Board of Directors.